Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥503m2026-01-01 → 2026-06-30StandaloneNet sales
Revenue¥29m2025-01-01 → 2025-12-31StandaloneNet sales (5-year summary)
Revenue¥29m2025-01-01 → 2025-06-30StandaloneNet sales
Operating income−¥768m2026-01-01 → 2026-06-30StandaloneOperating income
Operating income−¥1.3bn2025-01-01 → 2025-06-30StandaloneOperating income
Ordinary income−¥761m2026-01-01 → 2026-06-30StandaloneOrdinary income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.3bn2025-01-01 → 2025-06-30StandaloneOrdinary income
Profit before tax−¥761m2026-01-01 → 2026-06-30StandaloneIncome before income taxes
Profit before tax−¥1.3bn2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Net income−¥762m2026-01-01 → 2026-06-30StandaloneProfit loss
Net income−¥2.1bn2025-01-01 → 2025-12-31StandaloneNet income loss (5-year summary)
Net income−¥1.3bn2025-01-01 → 2025-06-30StandaloneProfit loss
Total assets¥4.5bnat 2026-06-30StandaloneAssets
Total assets¥4.6bnat 2025-12-31StandaloneAssets
Total assets¥1.9bnat 2025-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥1.3bnat 2026-06-30StandaloneLiabilities
Total liabilities¥556mat 2025-12-31StandaloneLiabilities
Net assets / equity¥3.3bnat 2026-06-30StandaloneNet assets
Net assets / equity¥4.0bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.4bnat 2025-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥3.2bnat 2026-06-30StandaloneCash and deposits
Cash and deposits¥3.7bnat 2025-12-31StandaloneCash and deposits
Cash & equivalents¥2.9bnat 2026-06-30StandaloneCash and cash equivalents
Cash & equivalents¥3.4bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.1bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.2bnat 2024-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥1.0bn2026-01-01 → 2026-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.9bn2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.0bn2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow¥32m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥8m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥5m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥497m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥3.2bn2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥42m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-26.032026-01-01 → 2026-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-802025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-52.852025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio72.1%at 2026-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio87.6%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio74.1%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued29,319,700at 2026-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued29,291,600at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued24,961,600at 2025-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 438
ItemContextValueUnit
Proceeds from long term loans payable fin cfInterimDuration_NonConsolidatedMember100000000JPY
Repayment of long term loans payable fin cfPrior1InterimDuration_NonConsolidatedMember-52774000JPY
Repayment of long term loans payable fin cfInterimDuration_NonConsolidatedMember-55552000JPY
Repayments of lease obligations fin cfPrior1InterimDuration_NonConsolidatedMember-5072000JPY
Repayments of lease obligations fin cfInterimDuration_NonConsolidatedMember-5138000JPY
Proceeds from issuance of common stock fin cfPrior1InterimDuration_NonConsolidatedMember-JPY
Proceeds from issuance of common stock fin cfInterimDuration_NonConsolidatedMember17616000JPY
Purchase of treasury stock fin cfPrior1InterimDuration_NonConsolidatedMember-JPY
Purchase of treasury stock fin cfInterimDuration_NonConsolidatedMember-303000JPY
Net cash provided by used in financing activitiesPrior1InterimDuration_NonConsolidatedMember42153000JPY
Net cash provided by used in financing activitiesInterimDuration_NonConsolidatedMember496622000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1InterimDuration_NonConsolidatedMember-23217000JPY
Effect of exchange rate change on cash and cash equivalentsInterimDuration_NonConsolidatedMember1282000JPY
Net increase decrease in cash and cash equivalentsPrior1InterimDuration_NonConsolidatedMember-1023393000JPY
Net increase decrease in cash and cash equivalentsInterimDuration_NonConsolidatedMember-487879000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember2165918000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember3429561000JPY
Cash and cash equivalentsPrior1InterimInstant_NonConsolidatedMember1142525000JPY
Cash and cash equivalentsInterimInstant_NonConsolidatedMember2941682000JPY
Directors compensations sgaPrior1InterimDuration_NonConsolidatedMember50136000JPY
Directors compensations sgaInterimDuration_NonConsolidatedMember65382000JPY
Salaries and allowances sgaPrior1InterimDuration_NonConsolidatedMember97504000JPY
Salaries and allowances sgaInterimDuration_NonConsolidatedMember105045000JPY
Research and development expenses sgaPrior1InterimDuration_NonConsolidatedMember1017169000JPY
Research and development expenses sgaInterimDuration_NonConsolidatedMember766164000JPY
Business consignment expenses sgaPrior1InterimDuration_NonConsolidatedMember40483000JPY
Business consignment expenses sgaInterimDuration_NonConsolidatedMember57893000JPY
License fee sgaPrior1InterimDuration_NonConsolidatedMember13278000JPY
License fee sgaInterimDuration_NonConsolidatedMember171831000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2026-08-07
Semi annual accounting period cover pageFilingDateInstant
Original text (Japanese)第23期中(自 2026年1月1日 至 2026年6月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長 浦田 泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目1番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03-5472-1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員 秦 耕平
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目1番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-5472-1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員 秦 耕平
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant-
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant-

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2025-12-31pass rounding
balance sheet identitynon_consolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2026-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2026-06-30pass